Medartis Holding AG represents a strong set of values and corporate philosophy. The company is committed to innovation, quality, and patient-oriented solutions in the field of medical technology. Medartis focuses on designing and manufacturing surgical implants for orthopedic and traumatology applications, catering to the needs of surgeons and patients alike. With a dedication to continuous improvement and customer satisfaction, Medartis aims to provide advanced and reliable implant systems that enhance patient outcomes and promote faster recovery. The company's steadfast commitment to excellence, along with its customer-centric approach, makes Medartis Holding AG a trusted name in the medical technology industry.

Medartis Holding AG is primarily present in Switzerland and operates internationally. As a leading manufacturer of medical devices, the company provides innovative solutions for surgical fixation of bone fractures and osteotomies. With its headquarters in Basel, Medartis has a strong presence in Europe and a growing global footprint, serving healthcare professionals and patients across various countries and regions. The company's commitment to quality, research, and patient care has cemented its reputation as a trusted partner in the orthopedic industry.

Medartis Holding AG, a leading medical technology company, has achieved several significant milestones. The company has successfully developed and launched innovative surgical solutions, enhancing patient outcomes worldwide. Medartis Holding AG has expanded its global presence, establishing a strong market position in various regions. The company's commitment to research and development has led to the introduction of state-of-the-art implants and instruments, revolutionizing the field of orthopedic surgery. Medartis Holding AG continues to collaborate with renowned healthcare professionals, ensuring continuous advancements in its product offerings. Through its dedication to excellence and persistent pursuit of innovation, Medartis Holding AG remains at the forefront of the medical technology industry.

Medartis Holding AG is a renowned Swiss-based medical device company specializing in innovative surgical solutions for orthopedic and traumatology procedures. Founded in 1997, Medartis has established itself as a global leader in providing high-quality implants, instruments, and services to healthcare professionals. With a strong focus on research and development, the company offers a wide range of products designed to enhance patient outcomes and simplify surgical procedures. Medartis Holding AG's commitment to innovation, advanced technology, and collaboration with healthcare communities worldwide has solidified its position as a trusted partner in the field of orthopedic and traumatology surgery.

Medartis Holding AG faces competition from various companies in the market. Some of its main competitors include industry leaders in the medical devices sector, such as Zimmer Biomet Holdings, Stryker Corporation, and Johnson & Johnson. These companies also operate in the orthopedic implants industry, offering similar products and solutions to healthcare professionals and patients. Medartis Holding AG strives to differentiate itself through its innovative product offerings and dedication to quality and customer satisfaction. However, it continues to face fierce competition from these renowned players within the industry.

Medartis Holding AG is primarily active in the medical technology industry.

Medartis Holding AG is a leading medical technology company that specializes in the development and manufacturing of innovative surgical solutions for orthopedic and trauma surgery. Their business model revolves around providing high-quality and innovative products such as implants, instruments, and digital solutions to surgeons and hospitals worldwide. By focusing on customer needs and leveraging their expertise, Medartis aims to improve patient outcomes and enhance surgical experiences. With a strong commitment to research and development, the company continues to drive innovation in the field of orthopedic surgery, ensuring its position as a trusted partner in the global healthcare industry.

De Medartis Holding K/W is 62,09.

De Medartis Holding KUV is 2,68.

De AlleAktien Kwaliteitsscore voor Medartis Holding is 4/10.

De verwachte Medartis Holding omzet is 244,93 mln. CHF.

De verwachte Medartis Holding winst is 10,56 mln. CHF.

The Medartis Holding AG is a Swiss company that specializes in the development, production, and distribution of implants and instruments for the surgical treatment of bone fractures and deformities. The company's business model focuses on providing products in the fields of traumatology, hand surgery, foot surgery, and maxillofacial surgery. The Medartis Holding AG offers a wide range of products, including implants such as plates, screws, Kirschner wires, and nails. These implants are made from titanium or stainless steel to ensure the highest strength and stability. Additionally, the company offers instruments to support surgical procedures, including drills, saws, forceps, and scissors. All products are developed and manufactured in Switzerland to ensure the highest quality standards. The traumatology division is a key focus of the business model as it targets the treatment of fractures, breaks, and defects of the skeletal system. Here, the company offers a wide range of implants and instruments specifically designed for different types and areas of bone, such as hip, shoulder, hand, and foot surgeries. In the field of hand surgery, the Medartis Holding AG offers products for the treatment of hand and wrist injuries, diseases, and defects. This includes specialized implants such as finger and thumb plates that enable fast and precise bone fracture repair. Additionally, the company also offers instruments specifically designed for working with delicate tissues such as tendons and nerves. In the field of foot surgery, the company provides solutions for injuries, diseases, and deformities of the foot and ankle. This includes implants such as screws for the treatment of ankle fractures and bone deformities, as well as plates for stabilizing fractures in the toe and midfoot areas. Maxillofacial surgery is another area that the business model of Medartis Holding AG focuses on. Here, the company offers a wide range of implants for the treatment of jawbone injuries, defects, and pathologies. This includes implants for stabilizing bone fractures and for the reconstruction and regeneration of jawbone. In addition to its products, the company also offers training and educational programs for surgeons and medical professionals to ensure that its technology remains up to date and that its products can be used safely and effectively. Overall, the business model of Medartis Holding AG is based on the development and provision of high-quality implants and instruments for the treatment of bone fractures and deformities in various medical fields. Through its innovative products and solutions, the company has become a key player in the medical industry and will continue to play an important role in the future.

Medartis Holding keert een dividend van 0 CHF uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Medartis Holding of het bedrijf keert geen dividend uit.

De ISIN van Medartis Holding is CH0386200239.

Het WKN van Medartis Holding is A2JGBF.

De ticker van Medartis Holding is MED.SW.

Binnen de laatste 12 maanden betaalde Medartis Holding een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Medartis Holding naar verwachting een dividend van 0 CHF betalen.

De dividendrendement van Medartis Holding is momenteel .

Medartis Holding betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Medartis Holding betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 CHF verwacht. Dit komt overeen met een dividendrendement van 0 %.

Medartis Holding wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Medartis Holding van 26-11-2024 ter hoogte van 0 CHF te ontvangen, moest je het aandeel voor de ex-datum op 26-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 26-11-2024.

In het jaar 2023 heeft Medartis Holding 0 CHF aan dividenden uitgekeerd.

De dividenden van Medartis Holding worden in CHF uitgekeerd.